Company news
MaxCyte, Inc. news in 2023
MaxCyte, Inc.'s news releases, calls and decks from 2023, newest first.
MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023
December 10, 2023
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member
November 15, 2023
MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance
November 7, 2023
MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance
October 3, 2023
MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing
September 5, 2023
MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance
August 8, 2023
MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients
July 31, 2023
MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023
July 12, 2023
MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies
July 9, 2023
MaxCyte Signs Strategic Platform License with Lyell Immunopharma
July 5, 2023
MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance
May 9, 2023
MaxCyte to Report First Quarter 2023 Financial Results on May 10, 2023
April 11, 2023
MaxCyte Appoints Douglas Swirsky as Chief Financial Officer
March 26, 2023
MaxCyte Reports Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023
MaxCyte Establishes New Scientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
March 7, 2023
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Revenue Results and Provides 2023 Revenue Guidance
March 5, 2023
MaxCyte to Report Fourth Quarter and Full Year 2022 Financial Results on March 15, 2023 and Participate in Upcoming Investor Conferences
January 31, 2023
MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs
January 2, 2023